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Abstract
Introduction: Lymphedema is a frequent consequence of lymph node excision during breast cancer surgery.
Current treatment options are limited mainly to external compression therapies to limit edema development. We
investigated previously, postsurgical lymphedema in a sheep model following the removal of a single lymph node
and determined that autologous lymph node transplantation has the potential to reduce or prevent edema
development. In this report, we examine the potential of lymphangiogenic therapy to restore lymphatic function
and reduce postsurgical lymphedema.
Methods: Lymphangiogenic growth factors (vascular endothelial growth factor C (VEGF-C)) and angiopoietin-2
(ANG-2) were loaded into a gel-based drug delivery system (HAMC; a blend of hyaluronan and methylcellulose).
Drug release rates and lymphangiogenic signaling in target endothelial cells were assessed in vitro and vascular
permeability biocompatibility tests were examined in vivo. Following, the removal of a single popliteal lymph node,
HAMC with the growth factors was injected into the excision site. Six weeks later, lymphatic functionality was
assessed by injecting
125Iodine radiolabeled bovine serum albumin (
125I-BSA) into prenodal vessels and measuring
its recovery in plasma. Circumferential leg measurements were plotted over time and areas under the curves used
to quantify edema formation.
Results: The growth factors were released over a two-week period in vitro by diffusion from HAMC, with 50%
being released in the first 24 hr. The system induced lymphangiogenic signaling in target endothelial cells, while
inducing only a minimal inflammatory response in sheep. Removal of the node significantly reduced lymphatic
functionality (nodectomy 1.9 ± 0.9, HAMC alone 1.7 ± 0.8) compared with intact groups (3.2 ± 0.7). In contrast,
there was no significant difference between the growth factor treatment group (2.3 ± 0.73) and the intact group
indicating improved function with the molecular factors. An increase in the number of regenerated lymphatic
vessels at treatment sites was observed with fluoroscopy. Groups receiving HAMC plus growth factors displayed
significantly reduced edema (107.4 ± 51.3) compared with nontreated groups (nodectomy 219.8 ± 118.7 and
HAMC alone 162.6 ± 141).
Conclusions: Growth factor therapy has the potential to increase lymphatic function and reduce edema
magnitude in an animal model of lymphedema. The application of this concept to lymphedema patients warrants
further examination.
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Lymphedema is a common complication of surgical
breast cancer treatment, developing in 20% to more
than 90% of patients, depending on the assessment cri-
teria employed [1]. If left untreated, the edema can lead
to recurring infections, impaired limb function, psycho-
social problems and, in extreme cases, malignant com-
plications and life-threatening infections. Most affected
individuals are offered some form of nonsurgical exter-
nal compression therapies to limit edema development,
but there is great interest in developing more effective
treatment options. One of the main problems, however,
is that we do not understand clearly why lymphedema
develops.
The pathogenesis of lymphedema is undoubtedly very
complex, with multiple factors likely contributing to the
development of chronic edema. In a previous report, we
argued that the lymph node itself may have an impor-
tant role in tissue fluid balance and observed that vascu-
larized autologous lymph node transplantation could
enhance lymphatic function and reduce edema signifi-
cantly [2]. In addition, however, one must consider the
damage to the lymphatic vessels that ensues when
lymph nodes are removed. While lymphatics normally
have an impressive capacity to regenerate following
injury, it is possible that this process fails to compensate
fully and that nonoptimal lymph transport conditions
predispose the patient to edema formation.
With this in mind, various groups have investigated
whether induction of lymphangiogenesis in animal mod-
els can impact lymphedema [3-6]. While the results are
generally positive, the use of relatively small animals for
these studies limits the amount of physiological infor-
mation that can be acquired. One advantage of using
sheep is that lymphatic function can be quantified rela-
tively easily, and any potential interventions are more
human-sized in their perspective [2,7].
In the experiments under consideration here, our
objective was to test the principle that the delivery of
lymphangiogenic growth factors into the nodal excision
site would enhance vessel regeneration, reestablish
lymph transport capabilities and reduce edema forma-
tion. In terms of identifying which factors to inject, vas-
cular endothelial growth factor C (VEGF-C) seemed like
an obvious choice, given its role in regulating new lym-
phatic vessel growth [8,9]. Another factor that we
decided to introduce into the lesion site was angiopoie-
tin-2 (ANG-2), which appears to play a role in the
maturation of newly formed lymphatic networks [10].
Having determined the animal model and the thera-
peutic molecules to deliver, we then focused on the
optimal delivery strategy. Osmotic minipumps or adeno-
viral vectors are commonly employed to introduce
molecules into the tissues. However, an evolving trend
in drug delivery is the use of minimally invasive, inject-
able drug delivery strategies where naturally derived
polymers have shown some therapeutic benefit on their
own. One such drug delivery system is the hydrogel
HAMC, a physical blend of hyaluronan (HA) and
methylcellulose (MC). Proteins diffuse readily through
HAMC, which also degrades over time [11]. Until now,
the use of HAMC has been restricted to delivery of
therapeutic molecules into the spinal cords of injured
rats [12,13], but its capacity for sustained, localized
release makes it an attractive candidate to deliver lym-
phangiogenic factors as well.
In this study, we report that the delivery of VEGF-C
and ANG-2 from HAMC into the nodal excision site
has a positive impact on lymphatic function and reduces
the magnitude of edema.
Materials and methods
A total of 60 randomly bred female Dorset sheep (24-45
kg) were used in this study. Animals were given free
access to food and water for an observation period of 1
week preceding surgery. To prevent infection, duplocil-
lin was administered intramuscularly 1 day prior to sur-
gery and 2 days postoperatively, and subcutaneous or
intramuscular injections of bupernorphine were given
postoperatively for pain management. All animal experi-
m e n t sw e r ea p p r o v e db yt h ea n i m a lc a r ec o m m i t t e ea t
Sunnybrook Health Sciences Centre and conformed to
the guidelines set by the Canadian Council on Animal
Care and the Animals for Research Act of Ontario. All
media and reagents were purchased from Sigma Aldrich
(Ontario, Canada) unless otherwise stated. VEGFC156S
was utilized exclusively throughout this study and is
referred to as VEGF-C throughout the remainder of the
article.
Formation and sterilization of HAMC
The formulation and sterilization of HAMC was modi-
fied from Gupta’s description [11]. To prepare the
HAMC components, a 0.5 wt/vol solution of methylcel-
lulose (MC; M7140) in distilled water was created using
a dispersion technique. Briefly, MC was added to one
third of distilled water at boiling, and once completely
wetted, the remaining two thirds of distilled water (cold)
were added. The solution was placed in 4°C until com-
pletely dissolved. Sodium hyaluronate (HA; molecular
weight 1500 kDa, NovaMatrix, Akershus, Norway) was
dissolved in distilled water to obtain a 0.1 wt/vol
solution. Both solutions were sterile filtered through a
0.22-μm polyethersulfone membrane filtration system
(Nalgene, New York, USA) and lyophilized under sterile
conditions. To produce growth factor-supplemented
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Canada) and ANG-2 (R&D Systems) were combined
with sterile filtered phosphate-buffered saline (PBS) in a
laminar flow hood and mixed to ensure homogeneous
dispersion of proteins within the polymer matrix.
Methylcellulose was then added, and the mixture was
vortexed to dissolve the MC. Last, hyaluronan was
added and the solution was vortexed and incubated
o v e r n i g h ta t4 ° Ct oa l l o wH At od i s s o l v ei n t ot h eM C
solution. Final concentrations of either 1 or 3 μg/ml of
growth factors were used throughout the study as
indicated.
Release rates
To determine the release profile of the growth factors
from HAMC, 1 ml of growth factor-infused HAMC (1
or 3 μg/ml) was loaded manually into a 3-ml tuberculin
syringe. The gel solution was then injected into 9 ml of
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 0.5% fetal bovine serum (FBS) in a 15-ml
Falcon tube. Growth factor release was assessed at 37°C
over a 256-hr time period. At each time point, all media
were removed and stored at -20°C for further analysis
by enzyme-linked immunosorbent assay (ELISA; R&D
Systems). Fresh media were then added to each tube,
and the experiment was continued. As an internal con-
trol, 1 μg/ml and 3 μg/ml samples of each growth factor
(in 0.5% FBS-supplemented media) were kept at 37°C
for 256 hr.
Release rate in presence of hyaluronidase
The above release rate experiment was repeated in the
presence of the hyaluronan degrading enzyme hyaluro-
nidase (0.5 U/ml to 50 U/ml) in PBS at pH 5.5, the opti-
mum pH for this enzyme (HAase; bovine testicular
hyaluronidase).
Cell culture of bovine lymphatic endothelial cells
The primary bovine lymphatic endothelial cells utilized
in this study were generously provided by Dr. Dumont
(Sunnybrook Health Science Center, Ontario, Canada).
Cultures were maintained in 10% FBS in DMEM on
uncoated plates at 37°C and 5% CO2.C u l t u r e sw e r e
supplemented with 10 n/g of VEGF-C to stimulate cell
growth. Once cultures reached 70% confluency, they
were used in bioactivity experiments.
Bioactivity of VEGF-C156S and Ang-2 released from
HAMC
To ensure that the concentrations of VEGF-C and Ang-
2 introduced into the drug delivery system were capable
of activating target receptors in lymphatic endothelial
cells (LEC), we performed the following experiments.
Bovine LEC cultures were serum-starved overnight in
DMEM supplement with 0.5% FBS to minimize signal-
ing through the lymphangiogenic pathways of interest.
Following the starvation period, cultures were stimulated
in one of two ways. In the case of Western blot analysis
of VEGFR-3, HAMC (containing 3 μg/mL of both
V E G F - Ca n dA N G - 2 )w a sa d d e dd i r e c t l yo n t ot h e
bovine plates, and cultures were stimulated for 24 hr.
To further reduce background signaling through the
Tie-2 receptor, cultures were incubated with release
media for 10 min. To form this release media, VEGF-C
a n dA N G - 2( l o a d e da t3μg/mL) were released from
HAMC for 8 hr, and then the resultant supernatant was
centrifuged to remove HAMC. As controls, cultures
were also treated with VEGF-C (200 ng/ml) and ANG-2
(800 ng/ml) in 5 ml of 0.5% FBS in DMEM to deter-
mine the baseline signaling levels through each receptor.
Furthermore, 1 ml of HAMC not loaded with growth
factors was included as a vehicle control. Following
treatment, cells were lysed for 30 min in phospholipase
C-g lysis buffer (50 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) pH 7.5, 150 mM sodium
chloride, 10% glycerol, 1% Triton X-100, 1 mM ethylene
glycol tetraacetic acid, 1.5 mM magnesium chloride, 10
mM sodium fluoride, 10 mM sodium pyrophosphate, 1
mM sodium orthovanadate and protease inhibitor cock-
tail (Roche Diagnostics, DE, USA) for 30 min on ice,
centrifuged, and the supernatants of each sample were
collected and then immunoprecipitated for VEGFR-3
(C-20, SC-321, rabbit polyclonal antibody; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and Tie-2 (C-20,
SC-324, rabbit polyclonal antibody; Santa Cruz Biotech-
nology) overnight at 4°C. Samples were resolved on 8%
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) gels and transferred to a polyvinyli-
dene fluoride membrane (GE Healthcare, Ontario,
Canada). Blots were blocked in either 5% BSA or 3%
milk overnight. The following day samples were incu-
bated in primary antibody (1:1000 anti-phosphotyrosine
4G10; Millipore, Ontario, Canada), Tie-2 and VEGFR3
at 4°C overnight. Blots were then incubated in a horse-
radish peroxidase-linked secondary (1:10,000, Bio-Rad,
Ontario, Canada) for 45 min at room temperature and
developed using a chemiluminescence kit (Supersignal
West Pico; Thermo Scientific, Ontario, Canada).
In vivo biocompatibility of HAMC
Sheep were fasted 24 hr prior to anesthesia induction.
The animals were anesthetized initially by 15-ml intrave-
nous injection of sodium pentothal. Subsequently, 2.0-
3.5% isofluorane was delivered through an endotracheal
tube via a Moduflex Dispomed machine with Hallowell
respirator for surgical maintenance. The dorsal surface
of each animal was shaved, washed with soap and water
and prepped with alcohol to remove all existing
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of HAMC and HAMC dually infused with VEGF-C and
ANG-2 were administered through 25-gauge needles.
Equal volumes of saline and bradykinin (1 mg/ml)
served, respectively, as the negative and positive con-
trols. Injections were administered in duplicate once
hourly for the first 3 hr (255, 195, 135, 75 min) and
then at 45, 30 and 15 min. Following injections at 15
min, 100 μLo f
125I bovine serum albumin (
125I-BSA)
(0.364 mg/ml; Perkin Elmer,O n t a r i o ,C a n a d a )a n d2 5
ml of Evans blue dye (EB) were introduced through a
catheter in the cephalic vein, following which the cathe-
ter was flushed with 5 ml of heparinized saline. A 15-
min time period was then allowed to elapse to allow
radioactivity and dye to accumulate at points of inflam-
mation, at which point the animal was killed. Skin
encompassing the injection points was removed and
photographed with a Nikon digital camera (model Cool-
Pix 4500). Each injection area was then punched out
individually using a 2.54-cm cork borer, placed in 10%
formalin and measured for radioactivity in a gamma
counter (1282 Compugamma CS Universal gamma
counter; LLK Wallas, Turku, Finland) to quantify
125I-
BSA accumulation. Hematoxylin and eosin staining was
performed on 7-μm paraffin-embedded cross-sections of
the injection areas to determine neutrophil infiltration.
On the basis of preliminary results, it became necessary
to assess inflammation induction over a longer period of
time, and as a result intradermal injections of HAMC
(with and without growth factors) were introduced into
nonanesthetized sheep at time points corresponding to
24 and 128 hr prior to being killed.
Induction of lymphedema and growth factor therapy
Lymphedema induction was conducted as previously
described by Tobbia et al. [2,7]. Fasting and anesthesia
induction were performed as described in the previous
section. Surgical areas were shaved, washed with soap
and water and disinfected with 70% alcohol. A vertical
incision (6-8 cm) was made over the lateral aspect of
the popliteal region in the hindlimb and the popliteal
fossa was exposed. Following identification of the popli-
teal node in its surrounding fat pad, the pre- and post-
nodal lymphatics were ligated and the node was excised.
At this time, growth factor therapy was introduced. Pre-
prepared HAMC (1 ml preloaded into a 3-ml syringe
with a blunted 18-gauge needle) was introduced into the
area of nodal excision. To increase the retention of
HAMC at this site, the fat pad pocket was then carefully
sealed with absorbable suture. In the case of sham sur-
geries, the popliteal fat pad was exposed but undis-
turbed. A piece of saline-soaked gauze was applied to
the area for 10 min to duplicate the length of time
needed to perform the growth factor treatment surgery.
The animals were returned to their holding pens after
recovery from the anesthetic.
Edema assessment
The hind legs were shaved and leg circumference mea-
surements were taken at a point 10 cm distal to the
hock (tarsus). This landmark was highlighted with a
skin marker for subsequent measurements postopera-
tively at the same location. The limb circumferences
were divided by the original (presurgical value) and
expressed as percentage change over time. To compare
the edema outcomes in the various groups, the percen-
tage change in limb circumference was plotted against
time, and graphical integration of the area under the
curves was calculated using the trapezoidal rule.
Quantitative assessment of lymphatic function
The primary role of the lymphatic system is to trans-
port protein and fluid from the interstitium back to
the venous system. Therefore, the ability to monitor
the transport of a radiolabeled protein through the
lymphatic system and its accumulation in blood is a
measure of lymphatic functionality. This method has
been used in several previous studies by our group
[2,7]. All animals were fasted, and anesthetic was
induced as described above. Evans blue dye (1% in sal-
ine) was injected subcutaneously above the hind leg
hoof to enhance visualization of the prenodal lympha-
tic vessels. An incision was made through the skin and
subcutaneous tissues over the lower lateral aspect of
the hindlimb, and a single vessel was cannulated with
a 26-gauge angiocatheter. Saline (100 μl) was injected
into the cannula over 30 seconds to check for leaks.
Radiolabeled BSA (
125I-BSA, 0.364 mg/ml, in a 100-μl
volume) was then injected over a 60-second period
into the prenodal lymphatic vessel and flushed with
100 μl of saline. Blood samples were taken from a
neckline inserted into the jugular vein at time 0, and
every 5 min up to 1 hr and then every 30 min up to
2 hr. Fluoroscopic imaging was then conducted and
the animals were killed (20 ml euthanyl, 240 mg/ml,
administered intravenously). It was determined that
our radiolabeled tracer was undergoing some break-
down upon introduction into the animal. To determine
the extent of the breakdown, trichloroacetic acid preci-
pitations were performed on 2-hr plasma samples from
each animal. Supernatant and pellet samples were
compared to equivalent volumes of unprecipitated
plasma to determine the amount of bound iodine.
Plasma samples (1 ml) were then placed in the external
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125I-BSA accumulations
in blood over time. These values were expressed as a
percentage of the total value of radioactivity (counts
per minute) injected and corrected to reflect only BSA
still bound to its radiolabel. These values were then
plotted versus time. To allow comparison between the
experimental groups, the graphical integration of the
area under each curve was calculated using the trape-
zoidal rule.
Fluoroscopy
Immediately following the lymphatic function studies,
imaging was performed. Approximately 1 mL of lipiodol
(Ultrafluid; E-Z-EM Canada, Inc., Anjou, Quebec,
Canada) was injected into the angiocatheter placed in
the upstream popliteal prenodal vessel and the lympha-
tics/nodes were visualized using a mobile fluoroscopy
system (BV Pulsera; Philips Healthcare, Andover, MA,
USA).
Statistical analysis
All data are expressed as means ± SEM unless otherwise
stated. The data were analyzed with linear regression or
one-way ANOVA followed by a one-sided Dunnett’s t-
test where indicated. We considered P <0 . 0 5t ob e
significant.
Figure 1 Percentage cumulative release of angiotensin-2 (ANG-2) and vascular endothelial growth factor (VEGF-C) from HAMC. (a)
VEGF-C and (b) ANG-2 display similar release profiles in which approximately 50% of initially loaded protein (1 or 3 μg) is released into the
surrounding media in the first 32 hr. Following this initial diffusion, controlled phase release rates then plateau. Complete dissolution of HAMC
(128 hr) increases recovery of both factors to 100%, suggesting that matrix degradation also plays a role in release. Data are shown as means ±
SEM (n = 3). Control (square), 1 μg (triangle), 3 μg (circle).
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Release rates
Release rates in static cultures
Figure 1 displays cumulative release rate profiles in
which each VEGF-C (Figure 1a) and ANG-2 (Figure 1b)
(1 or 3 μg/ml) is continuously released from HAMC
over a period of 128 hr. Within this time, growth factor
recovery was approximately 50%, with the majority of
releases occurring by hour 32, indicating that about half
of the initially loaded protein can be released from
HAMC through diffusion. These results correspond to
those previously reported for release profiles of growth
factors from HAMC [11,13]. When HAMC had comple-
tely degraded/dissolved into the media over the 2-week
period, growth factor recovery was approximately 100%,
suggesting that matrix degradation may be needed for
complete growth factor release.
Release rate in the presences of Hyaluronidase
Hyaluronidase (HAase) is one of the primary enzymes
involved in hyaluronan degradation, cleaving the b1-4
glycosidic bonds of this protein. This enzyme can be
found both on the cell surface (HYAL2) and within the
lysosome (HYAL1), and high levels of this enzyme are
often associated with high levels of hylauronan turnover
[14,15]. Since it was unknown whether the popliteal fat
pad would contain relatively low or high levels of
HAase, a dilution series of HAase activity levels was
used to assess the potential effect this enzyme could
have on release rates from HAMC. The activity level, 50
U, is representative of the highest natural tissue level of
this enzyme found within the human body (liver). In the
presence of hyaluronidase, HAMC displayed dose-
dependent release of growth factors that correlated with
increasing hyaluronidase concentration (Figure 2). More
ANG-2 was released in the presence of hyaluronidase
(50 and 5 U) in comparison to controls (no HAase),
reaching significance at 24 hr. While a similar trend is
observed for VEGF-C release in the presences of HAase,
groups were not significantly different, most likely due
to increased growth factor instability at the low pH
used. Ultimately, this experiment revealed that the pre-
sence of hyaluronidase at the site of HAMC injection
will likely influence growth factor release.
Bioactivity
Sequence homologies
It was necessary to determine whether the growth fac-
tors released from HAMC remained bioactive, that is,
could bind to their target receptors and activate their
respective signaling cascades in sheep. The growth fac-
tors employed in this study are human derived and thus
share only partial homology with those of sheep. Specifi-
cally, human ANG-2 protein shares 89.6% homology
with its sheep counterpart (HomoloGene, NCBI). While
no data were available for ovine VEGF-C, it was deter-
mined that bovines (also a ruminant animal) and
humans share 88.3% homology (HomoloGene, NCBI).
The receptors for each of these ligands share similar
homologies at 86.8% for VEGFR-3 (between bovine and
human) and 95.4% for Tie-2 (between bovine and
human) (HomoloGene, NCBI). The homologies appear
to be sufficiently similar that one can expect reactivity
between the sheep receptors and their human ligands.
Stimulation of LEC cultures
On lymphatic endothelial cells, ANG-2 acts through the
receptor Tie-2, while VEGF-C165S is known to associate
exclusively with the receptor VEGFR3 [16]. Lymphatic
endothelial cell cultures [17] were stimulated with con-
ditioned media from either HAMC alone or HAMC
infused with ANG-2 and VEGF-C. Significantly, HAMC
infused with ANG-2 and VEGF-C induced an increase
in cognate receptor phosphorylation over HAMC condi-
tioned media alone (Figure 3). Interestingly, HAMC
conditioned media alone can induce receptor activation
of Tie-2, although levels did not reach those induced by
ANG-2. These results demonstrate that both ANG-2
and VEGF-C, when released from the HAMC vehicle,
can activate their cognate receptors in vitro.
Biocompatibility
Previous studies have shown that HAMC attenuates the
inflammatory response and promotes healing of the
dura when injected into the intrathecal space in either
control or spinal cord injury rats [11]. We felt it neces-
sary to determine whether similar results could be
expected upon introduction of growth factor-infused
HAMC in our sheep model.
Qualitative and quantitative assessment of vascular
permeability: Evans Blue and
125I-BSA study
An effective method to measure the induction of inflam-
mation is to quantify changes in vascular permeability.
This is achieved by monitoring the accumulation of
intravenously administered dye or radiolabeled protein at
the site of interest. In this study, we employed the use of
EB and
125I-BSA accumulation following interdermal
injections of HAMC. After sheep were killed, injection
areas were first examined for EB accumulation. The
outer and undersurface of the skin displayed slight blue
staining corresponding to HAMC injection areas at 1-4
hr (Figure 4a, inset). This color development was greater
than that exhibited by the saline controls (no color), but
not reaching the blue staining level visualized in the bra-
dykinin injections points at 0 min and 15 min. Injection
areas corresponding to 1 day and 1 wk did not show any
dye accumulation, suggesting that vascular permeability
had subsided by these time points (Figure 4a, inset).
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125I-BSA.
These results suggested that HAMC (regardless of
growth factor presence) induced a minimal level of
inflammation. Levels of radioactive BSA were approxi-
mately double those observed in saline-injected sites but
never reached the levels attained by bradykinin injection
(Figure 4a). Over a 1-wk period, the skin BSA levels
induced by HAMC remained relatively constant and ele-
vated in comparison to saline controls (only reaching sig-
nificance at the third and fourth hours following
introduction). We concluded that HAMC did induce
some transient inflammation over the monitoring period.
Histology
An increase in the presence of neutrophils was observed
compared to control injections at hour 4 (Figure 4b).
However, by the end of week 1, HAMC injection areas
resembled those of controls. This result suggested that
the mild inflammation induced by HAMC was
temporary.
Lymphatic transport function
The average tracer accumulation in blood is illustrated
for all groups in Figure 5a. The black line (intact limbs)
provides the reference point for the various
Figure 2 Hyaluronidase increases the release rate of VEGF-C and ANG-2. Increasing levels of hyaluronidase activity (U/ml) is accompanied
by increasing release of (a) VEGF-C or (b) ANG-2 from HAMC. Data are shown as means ± SEM (n = 3). Fifty units (red), 5 U (blue), 0.5 U (green),
and no enzyme (black) are shown. Significant differences in ANG-2 release were reached by hour 24 in both the 50 U and 5 U enzyme
concentration solutions. VEGF-C release did not reach significance. Significance in comparison to control levels (no HAase) was assessed by
ANOVA and Dunnett’s one-sided t-test and is indicated by asterisks. *P < 0.05.
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little BSA enters the blood immediately after lymph
node excision, because the lymphatics have been dis-
rupted. It is clear that sham surgical procedures impact
lymphatic function negatively, presumably because some
of the fragile vessels have been damaged (red line). By 6
wk after excision, the normal lymphatic regeneration
has improved lymph transport somewhat (gray line) and
this is similar to that observed with HAMC alone (green
line). Some improvement in lymphatic function was
noted in the group receiving HAMC plus growth factors
(blue line).
To determine whether the functionality changes were
significant, the areas under the curves were compared.
Lymph node removal was found to significantly reduce
functionality in the nontreated groups (nodectomy 1.9 ±
0.9 or HAMC alone 1.7 ± 0.8) in comparison to intact
controls (3.2 ± 0.7) (Figure 5b). Alternatively, values for
the growth factor-treated groups (2.3 ± 0.7) were not
significantly different from the values observed in both
sham and control groups. This indicates similar lympha-
tic functionality across all three groups (growth factor-
treated, sham and intact). Growth factor-treated limbs
did not return completely to the functionality levels
measured in intact limbs over the 6-wk period.
Fluoroscopy
In intact and sham surgical groups, there were clearly
visible popliteal lymph nodes with identifiable prenodal
and postnodal vessels (Figure 6a). Six weeks after lymph
Figure 3 Growth factors released from HAMC possess the ability to stimulate lymphatic endothelial cells. Purified bovine lymphatic
endothelial cells (LECs) were stimulated with conditioned media from HAMC alone or HAMC infused with ANG-2 and VEGF-C. As controls,
cultures were also treated with VEGF-C156S (200 ng/ml) and ANG-2 (800 ng/ml). Immunoprecipitated (a) Tie-2 or (b) VEGFR-3 activation was
assessed by phosphotyrosine (pTyr). Cultures treated with growth factor release media displayed increases in receptor phosphorylation levels in
comparison to negative controls (unstimulated and HAMC alone). Blots were stripped and reprobed to confirm similar receptor levels across
treatment groups. n = 2. Molecular weights of each receptor are indicated.
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lished, because both the afferent and efferent vessels
were visible and connected by an entanglement of newly
regenerated vessels (example in Figure 6b). These newly
formed vessels appeared to be fragile as indicated by the
frequent leaks in this area upon contrast agent infusion.
The irregular regeneration pattern and what appeared to
be partial filling of some of the vessels precluded mean-
ingful quantitative analysis between groups. However,
general trends were noted. In the HAMC alone group,
the regeneration pattern was similar to that observed in
the nodectomy group (example in Figure 6c). In the
Figure 4 HAMC induces minimal inflammation in sheep. Introduction of HAMC (HAMC alone (green)) and HAMC infused with 3 μg/ml of
ANG-2 and VEGF-C (blue) resulted in an increased accumulation of (a)
125iodine radiolabeled bovine serum albumin (
125I-BSA) in comparison to
saline (black) injections at corresponding time points. These vascular permeability increases reached significance at 3 and 4 hr postinjection;
however, they appeared to resolve over a 1-wk period. Bradykinin, a transient vascular permeability inducer, was used as a positive control (red).
Data are shown as means ± SEM (0-4 hr, n = 5; 24 and 168 hr, n = 2). Double lines indicate a change in scale. Significance in comparison to
saline was assessed by ANOVA with accompanying one-way Dunnett’s t-test. *P < 0.05. Similar results were obtained when Evans blue dye (EB)
accumulation was examined ((a) inset), saline 4 hr (1), HAMC 4 hr (2) HAMC + GFs 4 hr (3), HAMC 1 wk (4), HAMC + GF 1 wk (5). (b)
Hematoxylin and eosin-stained skin sections of injection areas were examined using a bright-field microscope at ×10 magnification. There were
areas of heavy neutrophil infiltration in HAMC injection areas at 4 hr (2) in comparison to saline controls (1). Neutrophil infiltrations appeared to
resolve over the next week in HAMC injection areas (3). Circle indicates an area of heavy neutrophil infiltration. Inset: Enlargement of cell
infiltration area depicting classical morphology of neutrophilic cells, ×100 magnification.
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Page 9 of 17Figure 5 Lymphatic functionality. (a) Removal of the popliteal lymph node results in lymphatic vessel damage and immediate assessment
(Nod T0) reveals that minimal
125I-BSA transport to plasma occurs (orange, n = 7). Growth factor treatment (blue, n = 8) at the time of node
removal resulted in an increase in
125I-BSA accumulation levels in plasma over 2 hr in comparison to nontreated groups, nodectomy (gray, n =
8) and HAMC (green, n = 6). Growth factor treatment accumulation levels did not return to those seen in sham (red, n = 7) and intact control
groups (black, n = 7). Points represent means. SEM was omitted for clarity. (b) The area under each curve was then tabulated for each individual
animal using the trapezoidal rule. Following node removal, nontreated groups (nodectomy, HAMC, Nod T0) had significantly less functionality at
6 wk in comparison to the intact group. In contrast, functionality in the growth factor treatment group was similar to the intact group. Each bar
represents mean ± SEM. Significance in comparison to control levels (intact limbs) was assessed by ANOVA and Dunnett’s one sided t-test. *P <
0.05. BSA, bovine serum albumin.
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Page 10 of 17limbs receiving HAMC plus growth factors, there
appeared to be an increase in the number of regenerated
vessels (Figure 6d).
Edema
As expected, limb circumferences did not change over
time in the sham-treated animals. In contrast, the
removal of a popliteal lymph node resulted in edema
formation in 100% of animals. The presence of HAMC
plus growth factors appeared to produce the best results
in terms of reducing edema levels. Typical examples
from each group are illustrated in Figure 7a.
Similar to the lymphatic functionality experiment, the
areas under the curves were used to conduct quantita-
tive comparisons between groups (Figure 7b). Growth
factor-treated groups displayed edema magnitudes
slightly greater than but not significantly different to
sham levels (107.4 ± 51.3 and 59.2 ± 62.5, respectively).
Nontreated groups displayed significantly greater edema
levels in comparison to the sham group (nodectomy
219.8 ± 118.7 and HAMC 162.6 ± 141). This result sug-
gests that growth factor treatment has the ability to
reduce edema magnitude following lymph node
removal.
When we plotted all of the individual lymphatic func-
tion data versus their corresponding edema measure-
ments at 6 wk for all groups, we observed a significant
negative correlation (P = 0.001) (Figure 8). That is, the
highest levels of lymphatic function correlated with the
lowest levels of edema, supporting the notion that
improvement in lymph transport capacity with growth
factors has potential for lymphedema treatment.
Discussion
In this study, we report that the addition of two lym-
phangiogenic growth factors to a nodal excision site
enhances lymphatic transport function and reduces the
edema burden in a sheep model of lymphedema. These
data suggest that molecular therapeutic approaches may
ultimately be effective in improving outcomes for breast
cancer patients with lymphedema. For this concept to be
valid, some discussion of animal models, choice of mole-
cules and drug delivery systems and comparisons with
other potential therapeutic approaches are warranted.
Choice of animal model for investigation of lymphedema
It is clear that new animal models need to be developed
to understand more fully the pathogenesis of
Figure 6 Fluoroscopy of popliteal fossa region. Fluoroscopic images of the lymphatic networks 6 wk following surgery were taken.
Representative images from each group are shown above. In sham preparation (a) at 6 wk, the popliteal lymph node (arrow) is visible as well as
several pre- and postnodal lymphatics. In the cases where nodes were removed (nodectomy (b) and HAMC (c)), at 6 wk a tangled network of
lymphatics is visible at the surgical site, suggesting some lymph continuity has been reestablished through natural lymphangiogenesis. Growth
factor-treated animals (d) displayed an increase in the number of vessels in the excision site. This increase in vessels may be responsible for the
increase in lymphatic functionality seen in this group. Circles indicate popliteal fossa region.
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[18]. The use of small animals, especially the mouse, has
been very beneficial in helping to elucidate the mole-
cules that play a role in lymphangiogenesis. However, a
major advantage of utilizing a larger animal, such as the
sheep, for lymphedema studies is that lymphatic func-
tion can be measured, something that is extremely diffi-
cult to achieve in a small species. In sheep, the pre- and
postnodal popliteal ducts are easy to identify, and some
of these are of sufficient size for cannulation. In this
Figure 7 Development of edema following popliteal lymph node excision in the presence and absence of growth factor therapy. (a)
Typical examples of edema formation in each treatment group (n = 1) are displayed. (b) The area under the curve (AUC) was calculated for
animals using the trapezoidal rule. Node removal (nodectomy (2)) and node removal with HAMC (3) usually resulted in a sharp increase in
edema formation over the first week and decreased marginally over the next 5 wk. In contrast, growth factor-treated groups displayed reduced
edema levels by 6 wk (4), statistically similar to sham levels (1). Each bar represents mean ± SEM. Sham n = 18, nodectomy n = 36, HAMC n =7 ,
HAMC + GF n = 7. Significance in comparison to sham levels was assessed by ANOVA and Dunnett’s one sided t-test. *P < 0.05.
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beled albumin to plasma provides a useful measure of
the lymph transport effectiveness of a given lymphatic
network. Therefore, following the injection of
125I-BSA
into prenodal lymphatic vessels, one would expect that
the mass transport rate of this protein tracer to plasma
would reflect the integrity of the lymphatic network in
question, a notion that is supported by the data in this
report.
In humans, lymph-venous anastomoses can form with
long-term lymphatic obstruction [19,20]. If such connec-
tions were to exist in our sheep experiments, the labeled
BSA would be diverted into the limb vasculature and
would not pass through the nodal excision site. How-
ever, over the many years we have used the sheep
model, we have never observed these connections in the
popliteal region. Presumably, the level of impediment
caused by nodal excision in the animal model is rela-
tively benign compared to that which occurs in humans
with cancer. In the human case, the surgical procedures
related to the removal of the cancer and lymph nodes
a r em u c hm o r ee x t e n s i v ea n dl i k e l yp r o v i d eas i g n i f i -
cantly greater insult to the lymphatic system than that
occurring in our experiments. In the latter case,
relatively robust lymphangiogenesis occurs and some
degree of fluid continuity is restored relatively quickly
so that the stimulus for lymph-venous connections in
the leg may not be as great as is the case with some
lymphedema patients.
In cancer patients, the removal of one or more lymph
nodes often gives rise to acute edema which resolves
successfully. It is, of course, the chronic form of edema
that occurs in a subgroup of patients that is most pro-
blematic. The exact conditions that drive the formation
of this subgroup are unknown. It has been suggested
that women with greater than average peripheral lymph
flow are more likely to develop lymphedema following
breast cancer surgery [21]. The authors postulated that
this predisposing factor might explain why lymphedema
develops in patients in which only a few nodes have
been removed. In all likelihood, lymphedema is the
result of a complex interplay between many factors (sur-
gery, lymph node removal, radiation, injury and predis-
posing characteristics) that lead to the development of
this condition. It should be noted that we are not
attempting to replicate the complex conditions experi-
enced by cancer patients in our model. Instead, our
model permits us to examine the properties of a single
Figure 8 Relationship between lymphatic functionality and edema magnitude. Functionality data (AUC at 2 hr) were plotted versus their
corresponding edema values at 6 wk, n = 36. The trend shows a negative correlation, suggesting that as lymphatic functionality increases,
edema magnitude at 6 wk decreases. Linear regression analysis revealed this trend to be significant, P = 0.001.
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principles that could be applicable to the human
condition.
There is no agreed-upon time beyond which one con-
siders edema to be chronic. For practical reasons, we
did not follow the animals beyond a 6-wk period. None-
theless, we feel that our sheep model is suitable for the
measurement of lymphatic-related physiological changes
over time and can provide a realistic framework for the
development of therapeutic measures and methods of
administration that are human-sized in perspective.
Drug delivery systems
There are many potential drug delivery approaches that
could be used to introduce lymphangiogenic growth fac-
tors. The HAMC system offers several advantages in
this regard. A hydrogel represents a network of water-
swollen polymer chains in which water is the dispersion
medium. When HAMC is placed within the body, it
absorbs water from the surrounding environment, the
pore sizes within the matrix expand and proteins are
released [22]. This characteristic property of hydrogels
accounts for the rapid burst release of growth factors at
the beginning of each release study. In the case of our
system, following this initial rapid release, rates appeared
to slow until HAMC had undergone dissolution. This
suggests that growth factors incorporated into the outer
regions of HAMC could readily diffuse into media, but
the diffusion distance may have been too great for those
incorporated into the core of HAMC, causing release to
plateau. Degradation of HAMC then allows for the
release of remaining factors.
Previous HAMC studies saw almost complete diffu-
sion-mediated release of a single growth factor from this
system over a 16-hr period [13], but in these experi-
ments the volume of HAMC used was 1000-fold less
than the volumes utilized in our report.
Hyaluronan is metabolized by hyaluronidase in vivo,
and it has already been shown that this enzyme can
affect the degradation of HAMC [11]. As anticipated,
increasing activity levels of HAase in our study were
associated with increasing release rates of both growth
factors. This result suggests that endogenous HAase
activity in the popliteal fossa may result in more rapid
release of lymphangiogenic factors in vivo than pre-
dicted from the in vitro experiments. While we do not
know the release profiles of VEGF-C and ANG-2 in
vivo, we expect that the release rates will depend upon
consumption of the factors (maintaining a concentration
gradient favoring release) in the popliteal fossa and the
presence of degrading enzymes, such as hyaluronidase.
We anticipate that the bioactivity of released factors will
be maintained over the course of the release, owing to
their incorporation into HAMC. The half-life of VEGF-
C in the circulation is less than 15 min; thus HAMC
will likely provide some protection to the growth factors
by controlling its release over time [23].
The HAMC drug delivery system contains numerous
components that could potentially invoke a reaction from
the host: the methylcellulose is synthetically manufactured,
hyaluronan is produced in bacteria and the growth factors
are all human derived. Nonetheless, the evidence pre-
sented in this report, including assessments of vascular
permeability and leukocyte infiltration, indicates that any
host response is minimal. This is supported by the litera-
ture where HA has been shown to attenuate the inflam-
matory response in several tissues [24].
Choice of growth factors and in vivo bioactivity
One of the most important questions in devising a
molecular strategy for lymphedema treatment is the
selection of the lymphangiogenic growth factor. In this
regard, VEGF-C seemed an obvious choice. VEGF-C is
required for the development of the lymphatic system as
well as for proliferation, migration and survival of LECs
[9]. It is also known that blocking signaling through its
receptor, VEGFR-3, results in regression of preexisting
lymphatic vessels. Recent studies in mice have revealed
that VEGF-C introduction increases the rate of damaged
v e s s e lr e c o n n e c t i o ni nc o m p a r i s o nt oc o n t r o l s[ 2 5 ] .
After lymph node excision and transplantation, VEGF-C
was observed to facilitate vessel connection to the trans-
planted tissue [26]. Furthermore, evidence has been
found that directly links VEGF-C signaling and lymphe-
dema. Point mutations identified in VEGFR-3 lead to a
hereditary form of lymphedema, known as Milroy’sd i s -
ease that presents with edema of the lower extremities
[27,28].
Another factor we decided to introduce into the lesion
site is angiopoietin-2. ANG-2 has been implicated in the
organization of the lymphatic system through the activa-
tion of the Tie-2 receptor. ANG-2-knockout mice dis-
play abnormal lymphatic patterning, disrupted lymphatic
endothelial-smooth muscle cell interactions as well as
subcutaneous edema and chylous ascites, indicting an
obligatory role for ANG-2 in lymphatic system develop-
ment [10,17].
Overall, this study revealed that both growth factors
appear to be protected from inactivation while incorpo-
rated in HAMC until their release, when they can in
turn bind and activate target receptors involved in lym-
phangiogenic signaling. Owing to close homology
between both bovine and ovine ligands and receptors,
these results suggest that similar results would likely be
obtained with ovine cells, which was supported by new
vessel growth in the fluoroscopic images.
Additionally, we found that HAMC appears to
potentiate Tie-2 phosphorylation by ANG-2. Specifically,
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tion demonstrated by the increased presence of a second
band in these cultures. As HAMC undergoes dissolu-
tion, the viscosity of media surrounding the cells
increases, which may alter the interaction of Tie-2 with
ANG-2 dimers (which form spontaneously in solution),
perhaps increasing their association time, explaining the
above result.
This study also indicated that HAMC may possess the
surprising ability to activate the receptor tyrosine kinase
(RTK) Tie-2. It is well known that low molecular weight
hylauronan fragments play a role in endothelial cell pro-
liferation and migration through activation of particular
RTKs [29]. Typically, these fragments range from 3 to
16 oligosaccharides in length [30]. However, the hylaur-
onan utilized was initially 1500 kDa, and while small
amounts of random cleavage may occur, this seems like
an unlikely cause of receptor activation. A second, more
plausible theory is that through an association with
CD44, hyaluronan indirectly influences Tie-2 signaling.
Hylauronan can directly bind CD44, causing the cell
surface receptor to cross link [31]. This cross linking
has been shown to influence integrin signaling [31],
which in turn can influence Tie-2 activation [32]. All
three are common receptors found on the surface of
endothelial cells, and therefore association with CD44
could indirectly affect Tie-2 signaling. The ability of
HAMC to independently activate a RTK such as Tie-2
may provide an additional advantage to the lymphangio-
genic process, working synergistically with the ligand
ANG-2 to improve functionality.
Other factors to consider
Our results suggest that prolymphangiogenic growth fac-
tors can have a positive impact on lymphatic function
and improve edema outcomes. However, there are sev-
eral conceptual issues that may need refinement in future
investigations. First, there is evidence that lymphangio-
genesis is a two-phase process. The initial phase involves
activation of endothelial cells and sprouting, while the
second phase involves maturation of these vessels.
Maturation includes smooth muscle cell recruitment,
which appears to play an important role in the orienta-
tion of newly formed vessels [10]. With this in mind, it
may be possible to build a system to control the temporal
release of the growth factors to mimic more closely the
endogenous realities. It should be noted, however, that
the dual factor approach and the doses we utilized in this
study had a significant impact on lymphatic function and
edema resolution. This information provides a useful fra-
mework on which to optimize lymphangiogenic thera-
peutic approaches in future studies.
A second issue involves the signaling ability of
VEGFC156S (utilized here) versus its wild-type
counterpart. The wild-type ligand has the ability to bind
both VEGFR2 and VEGFR3 receptors, while
VEGFC156S is an agonist only to VEGFR3. Signaling
through VEGFR2, which is found predominantly on vas-
cular endothelium, causes increased permeability, an
event that we wanted to minimize in our study. How-
ever, upon initial characterization, it was noted that
VEGFC156S signaling in LECs was different from
VEGF-C [16]. It was postulated that activation of
VEGFR2 on LECs might be needed to induce maximal
lymphangiogenic signaling. In any event, it is clear that
manipulation of lymphangiogenesis in vivo is a complex
issue and that optimal conditions (choice of factor,
dosage and timing of application) require further
investigation.
Comparison of lymphangiogenic based therapies with
other potential approaches
The appeal of lymphangiogenic-based therapies for the
treatment of lymphedema is easy to understand. This
type of treatment has the potential to reverse the disease
state by facilitating naturally occurring processes. How-
ever, processes such as lymphangiogenesis are complex
and not fully understood yet. Furthermore, while mole-
cular therapies have shown benefits in breast cancer-
related lymphedema, the exact nature of the defect that
causes lymphedema is still unknown, and therefore the
most appropriate approach to the treatment method for
this disease must still be determined.
Autologous lymph node transplantation is an alterna-
tive experimental treatment for lymphedema. It is well
documented that removal of the lymph nodes greatly
increases the chance of developing lymphedema, espe-
cially if this is combined with radiotherapy [33]. In a
previous report, we demonstrated that a successful vas-
cularized popliteal node transplant in sheep could effec-
tively restore lymphatic function and limit or prevent
edema development when applied at the time of nodal
excision [2]. Indeed, Becker and colleagues [34] trans-
planted femoral nodes into the axillary region of 24
postmastectomy lymphedema patients using microsurgi-
cal procedures followed by manual drainage (physiother-
apy) during the first 3 months. Overall, edema
resolution was good, especially in those individuals in
whom the lymphedema was of the shortest duration.
Surgical complexities and potential donor site morbidity
issues complicate the application of lymph node trans-
plantation in clinical practice.
Conclusions
The HAMC drug delivery system has been successfully
adapted for the introduction of prolymphangiogenic
molecular factors to a nodal excision site. The growth
factors employed in this study, VEGF-C and ANG-2,
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significantly increased lymph transport and reduced the
magnitude of edema formation. Results from this study
highlight the potential of molecular therapies for lym-
phedema patients.
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